Author:
Denton Christopher P.,Black Carol M.
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. Rose NR, Leskovsek N: Scleroderma: immunopathogenesis and treatment. Immunol Today 1998, 19:499–501.
2. Silman AJ: Scleroderma-demographics and survival. J Rheumatol Suppl 1997, 48:58–61.
3. Black CM, Silman AJ, Herrick A, et al.: Alpha interferon does not improve outcome at one year in patients with diffuse cutaneous scleroderma. Arthritis Rheum 1999, 42:299–305. Another negative study for an agent previously in clinical use for scleroderma. The overall conclusion was that Interferon A is of no value in the treatment of scleroderma and may in fact be deleterious.
4. Clements PJ, Wong WK, Seibold JR, et al.: High-dose (HI-DPA) vs low-dose (LO-DPA) penicillamine in early diffuse systemic sclerosis (SSc) trial: Analysis of trial. Arthritis Rheum 1997, 40:S854. One of the most rigorously controlled interventional studies in scleroderma performed to date. Unfortunately the overall finding was that conventional dose D-penicillamine was no more effective than a very low dose, implying a lack of efficacy for the high-dose regimen.
5. Van den Hoogen FH, Boerbooms AM, Swaak AJ, et al.:Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24-week randomized, double-blind trial, followed by a 24-week observational trial. Arthritis Rheum 1998, 40:S.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献